Turn Therapeutics Inc (TTRX) FinancialsTTRXFinancialTurn Therapeutics Inc

Evaluating the bottom line, Turn Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -686.28%, provide a clear picture of how effectively TTRX converts its operational activities into shareholder value.

In the context of the broader market, TTRX competes directly with industry leaders such as BCYC and AMRN. With a market capitalization of $307.02M, it holds a leading position in the sector. When comparing efficiency, TTRX's gross margin of N/A stands against BCYC's 100.00% and AMRN's 35.51%. Such benchmarking helps identify whether Turn Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows that TTRX has been struggling with net income losses, with the latest reported net income of -5,849,734 USD for Q2 2026. The forward P/E ratio is currently at 0, reflecting the company's lack of positive earnings expectations in the near future.